New Directions in Imaging Neuroendocrine Neoplasms

Refardt, Julie; Hofland, Johannes; Wild, Damian; Christ, Emanuel

doi:10.1007/s11912-021-01139-2

Cited by 6 publications

(6 citation statements)

References 100 publications

(154 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Большинство НЭО экспрессирует на поверхностной мембране опухолевых клеток соматостатиновые рецепторы (ССР), при этом плотность ССР находится в прямой зависимости от степени дифференцировки опухоли. Данный факт открывает возможности для создания РФП на основе лигандов к ССР [37][38][39]. Наиболее широко внедренными в клиническую практику РФП из группы 68 Ga-ДОТА пептидов являются 68 Ga-DOTA-Phe1-Tyr3-Octreotide ( 68 Ga-DOTATOC), 68 Ga-DOTA-NaI3-Octreotide ( 68 Ga-DOTANOC) и 68 Ga-DOTA-Tyr3-Octreotate ( 68 Ga-DOTATATE).…”

Section: Resultsunclassified

“…К достоинствам 68 Ga-ДОТА пептидов относится низкий уровень накопления РФП в нетаргетных зонах, интенсивная и длительная фиксация на опухолевых клетках, высокое соотношение опухоль/фон [37,38].…”

Section: Resultsunclassified

“…Особый интерес представляет возможность использования уже известных меченных соединений, которые применяются в радионуклидной диагностике других патологических состояний, например 68 Ga-ПСМА или 68 Ga-FAPI. Тем не менее их эффективность в диагностике МРЩЖ требует изучения [37,38,54].…”

Section: Resultsunclassified

See 2 more Smart Citations

PET/CT with various radiopharmaceuticals in the complex diagnosis of medullary thyroid carcinoma: a review

Tsentr,

Ertman,

Ryzhkova

2023

Lučevaâ diagn. ter.

View full text Add to dashboard Cite

INTRODUCTION: Medullary carcinoma is a rare malignant neuroendocrine tumor of the thyroid gland. Medullary thyroid carcinoma (MTC) has no specific clinical symptoms. Due to the absence of specific symptoms, the disease is usually diagnosed at the stage of metastatic lesions of regional lymph nodes, and sometimes, internal organs. The five- and ten-year survival after detection of distant metastases is 25% and 10%, respectively.OBJECTIVE: To analyze the available foreign and domestic literature to determine the role of PET/CT with various radiopharmaceuticals in the complex radiological diagnosis of MTC.MATERIALS AND METHODS: A search was made for scientific publications and clinical recommendations in the information and analytical systems PudMed, elibrary over the past ten years, dedicated to the diagnosis of MTC, including PET/CT with 18F-DOPA, 18F-FDG, 68Ga-DOTA peptides, etc. by keywords «medullary thyroid cancer», «medullary thyroid carcinoma», «PET/CT», «18F-L-dihydroxyphenylalanine», «18F-DOPA», «18F-DOPA», «68Ga-DOTA peptides», «68Ga-DOTA-peptides», «theranostics», «theranostics».RESULTS: The analysis of publications demonstrated the prospects for the use of PET/CT with various radiopharmaceuticals for the diagnosis of recurrent tumors and the prevalence of the process in biochemical recurrence of MTC, as well as the possibility of peptide-receptor radionuclide therapy for the treatment of advanced forms of the disease. The choice of radiopharmaceuticals is based on the results of laboratory diagnostics and conventional methods of anatomical imaging. PET/CT with 68Ga-DOTA peptides is performed to predict the effectiveness of peptide-receptor radionuclide therapy.CONCLUSION: PET/CT with various radiopharmaceuticals makes a significant contribution to the diagnosis of recurrent tumors, assessment of the prevalence of the tumor process and selection of patients for peptide-receptor radionuclide therapy.

show abstract

Section: Resultsunclassified

See 1 more Smart Citation

PET/CT with various radiopharmaceuticals in the complex diagnosis of medullary thyroid carcinoma: a review

Tsentr,

Ertman,

Ryzhkova

2023

Lučevaâ diagn. ter.

View full text Add to dashboard Cite

show abstract

“…Somatostatin receptor antagonists are not limited to active receptors and demonstrate several fold increased uptake and higher tumor-to-background ratio, in contrast to the previously described SSTR analogs, which require active receptor dependent internalization and intracellular retention for them to be effective. 36 Hence, SSTR antagonists are valid alternatives to SSTR agonists in patients with liver-dominant metastatic disease due to lower background liver activity and improved sensitivity for small lesions. 37…”

Section: Magnetic Resonance Imagingmentioning

confidence: 99%

Liver Imaging in Gastroenteropancreatic Neuroendocrine Neoplasms

Jeph,

Gupta,

Yedururi

et al. 2024

J Comput Assist Tomogr

View full text Add to dashboard Cite

The incidence of neuroendocrine neoplasms (NENs) has gradually increased over the past few decades with the majority of patients presenting with metastases on initial presentation. The liver is the most common site of initial metastatic disease, and the presence of liver metastasis is an independent prognostic factor associated with a negative outcome. Because NENs are heterogenous neoplasms with variable differentiation, grading, and risk of grade transformation over time, accurate diagnosis and management of neuroendocrine liver lesions are both important and challenging. This is particularly so with the multiple liver-directed treatment options available. In this review article, we discuss the diagnosis, treatment, and response evaluation of NEN liver metastases.

show abstract

“…Besides the well-established somatostatin receptor (SSTR) imaging with 68 Ga-DOTATOC/-TATE and –NOC, the radioisotope 64 Cu (copper) can be linked to DOTATATE with equivalent high image quality and diagnostic accuracy. Alternative approaches include SSTR antagonist such as 68 Ga-OPS202 also called 68 Ga-NODAGA-JR11 [ 9 ]. Preliminary data indicate a high metastasis detection rate and superior sensitivity compared to agonists in NET patients.…”

mentioning

confidence: 99%